ClinicalTrials.gg
CompletedNCT04110054Updated Mar 27, 2024Results posted

Evaluation of S-600918 in Adults With Refractory Chronic Cough

A Phase 2 interventional study of S-600918 and Placebo to S-600918 in Chronic Cough, sponsored by Shionogi. Completed at 136 sites in 6 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Shionogi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Chronic Cough with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Chronic Cough · United States.

Enrollment
7th of 37
406 · median 50
Started
2020
with 6 others
Phase 2
16 of 44
3 open now
Registered
18th of 44
by date

Among the 44 studies in Chronic Cough with a site in United States, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2020, is one of 16 in phase 2, and was the 18th registered.

Chronic Cough

142 studies on the registry are indexed under Chronic Cough; 39 are open to participants now.

Browse Chronic Cough studies →

Open to participants now

9 of the 44 studies in Chronic Cough with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Chronic Cough studies recruiting now, 10 (33%) set no upper age limit and 11 (37%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chronic Cough with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

03

Conditions studied

  • Chronic Cough

Browse trials for

Keywords

  • P2X3 receptor antagonist
  • Refractory chronic cough
  • S-600918
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Having chronic cough (including unexplained chronic cough) for at least 1 year.
  • If female and of , agreement to use one of the allowed methods.
  • Capable of giving signed .

Key Exclusion Criteria:

  • Currently smokes or uses potentially irritating inhalational agents (eg, e-cigarettes, smokeless cigarettes, vaping); stopped smoking or using potentially irritating inhalational agents within the last year; or has a smoking history of 20 pack-years or more.
  • Has or uncontrolled asthma.
  • Has a clinically unstable medical condition.
  • History of or ongoing significant psychiatric disorder.
  • History of respiratory tract infection or significant change in lung function or a pulmonary condition in the last 4 weeks.
  • History of in the last 5 years.
  • History of severe drug allergy.
  • History of alcohol or drug abuse in the last year or currently uses any form of marijuana or illicit drugs.
  • Has a finding on a chest x-ray or chest computed tomography (CT) scan in the last year.
  • Has systolic blood pressure > 160 mm Hg or diastolic blood pressure > 90 mm Hg.
  • Received S-600918 previously.
  • Received an drug in the last 3 months.
  • Received an angiotensin converting enzyme (ACE) inhibitor in the last 3 months or requires such treatment.
  • Has a positive serologic test for (HIV) antigen or antibody, virus surface antigen, or virus ribonucleic acid (RNA).
  • If female, pregnant or trying to become pregnant or breastfeeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
406 participants (actual)

Study arms

  • Experimental
    S-600918 50 mg

    Participants will receive 50 mg S-600918 orally once a day for 28 days.

    Drug: S-600918

  • Experimental
    S-600918 150 mg

    Participants will receive 150 mg S-600918 orally once a day for 28 days.

    Drug: S-600918

  • Experimental
    S-600918 300 mg

    Participants will receive 300 mg S-600918 orally once a day for 28 days.

    Drug: S-600918

  • Placebo comparator
    Placebo

    Participants will receive placebo to S-600918 orally once a day for 28 days.

    Drug: Placebo to S-600918

Interventions

  • DrugS-600918

    Tablets for oral administration

    Also known as: Sivopixant

  • DrugPlacebo to S-600918

    Tablets for oral administration

06

What researchers measure

Primary outcomes

  1. Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment

    Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour in 24 hours at each visit with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the log-transformed coughs per hour in 24 hours at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Number of Participants With 30%, 50%, and 70% Reduction in Number of Coughs Per Hour Over 24 Hours After 4 Weeks of Study Treatment

    The number of coughs per hour for 24 hours was measured using a cough monitor.

    Time frame: Baseline to Week 4

  2. Percent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment

    Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while awake at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while awake at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

    Time frame: Baseline to Week 4

  3. Number of Participants With 30%, 50% and 70% Reduction in Number of Coughs Per Hour While Awake After 4 Weeks of Study Treatment

    The number of coughs per hour while awake was measured using a cough monitor.

    Time frame: Baseline to Week 4

  4. Percent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment

    Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while asleep at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while asleep at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

    Time frame: Baseline to Week 4

  5. Change From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment

    Cough severity was assessed by the participant by a visual analog scale with numbers from 0 to 100. Results are presented as change from baseline. Reported change is based on a mixed model for the change in weekly cough severity score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the severity score at baseline as covariates. Higher scores indicated higher cough severity.

    Time frame: Baseline to Week 4

  6. Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21. Higher score indicates a better quality of life. Results are presented as change from baseline. Reported change is based on a mixed model for the change in LCQ Total Score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the LCQ Score of corresponding domain at baseline as covariates.

    Time frame: Baseline to Week 4

  7. Number of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points

    The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 2. A higher score indicates a better quality of life.

    Time frame: Baseline to Week 4

  8. Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)

    The ICIQ-SF is a questionnaire used to evaluate the frequency, severity, and impact of urinary incontinence on the quality of life. The questionnaire includes 3 items with responses measured on Likert scales, and 1 item that is measured via a qualitative response. The 3 nominal responses are summed to give the ICIQ score (this total ICIQ-SF score can range from 0 to 21), where a higher score indicates more severe symptoms. The 1 item remaining that is measured via qualitative response is not given a score; rather, the participant selects 1 description out of 8 possible descriptions of this item.

    Time frame: Baseline to Week 4

  9. Change From Baseline in Short Form (36) Health Survey (SF-36)

    The SF-36 is a 36-item questionnaire to assesses a participant's health status using 8 health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. The mental component reports the average of all the emotionally relevant items and the physical component reports the average of all the physically relevant items. Each component is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. A score of 0 is equal to maximum disability, and a score of 100 indicates no disability. Median change can range from -100 to 100. A positive median change indicates an improved outcome.

    Time frame: Baseline to Week 4

  10. Number of Responders as Assessed by Patient Global Impression of Change (PGIC)

    The PGIC is a patient-reported measure of overall health status and consists of 1 item adapted from the Clinical Global Impressions scale. The participant selects 1 description out of 7 possible descriptions of this item. The descriptions are numbered from 1 through 7, where lower numbers indicate better quality of life. Participants were considered responders if they reported "Very much improved", "Much improved", or "Minimally improved" from baseline on the PGIC assessment.

    Time frame: Week 4

07

Results

Posted Mar 27, 2024

Participant flow

Participant flow — Overall Study
MilestoneS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Started101103100102
Received at least 1 dose of study drug100103100102
Completed100999299
Not completed1483
Withdrew: Covid-19 reason other than ae0020
Withdrew: Withdrawal by subject0320
Withdrew: Adverse event1143

Outcome measures

PrimaryPercent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment

Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour in 24 hours at each visit with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the log-transformed coughs per hour in 24 hours at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage change
Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment
percentage changeS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Percent Change in Number of Coughs Per Hour in 24 Hours Following 4 Weeks of Study Treatment-55.16 (-62.80 to -45.94)-61.08 (-67.71 to -53.08)-65.32 (-71.37 to -57.99)-60.38 (-67.07 to -52.32)
Statistical analysis
  • S-600918 50 mg vs S-600918 150 mg vs S-600918 300 mg vs Placebo · ANCOVA · p = 0.9334 (P-value was evaluated at the 2-sided alpha level of 0.05.)
SecondaryNumber of Participants With 30%, 50%, and 70% Reduction in Number of Coughs Per Hour Over 24 Hours After 4 Weeks of Study Treatment

The number of coughs per hour for 24 hours was measured using a cough monitor.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Participants With 30%, 50%, and 70% Reduction in Number of Coughs Per Hour Over 24 Hours After 4 Weeks of Study Treatment
ParticipantsS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
≥ 30% Reduction55666661
≥ 50% Reduction38465049
≥ 70% Reduction24263127
SecondaryPercent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment

Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while awake at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while awake at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

Time frame:
Baseline to Week 4
Reported as:
Geometric mean · percentage change
Percent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment
percentage changeS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Percent Change in Number of Coughs Per Hour While Awake Following 4 Weeks of Study Treatment-55.77 (-63.61 to -46.25)-61.75 (-68.52 to -53.52)-66.33 (-72.43 to -58.89)-60.31 (-62.27 to -51.87)
SecondaryNumber of Participants With 30%, 50% and 70% Reduction in Number of Coughs Per Hour While Awake After 4 Weeks of Study Treatment

The number of coughs per hour while awake was measured using a cough monitor.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Participants With 30%, 50% and 70% Reduction in Number of Coughs Per Hour While Awake After 4 Weeks of Study Treatment
ParticipantsS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
≥ 30% Reduction55676761
≥ 50% Reduction41485146
≥ 70% Reduction22262925
SecondaryPercent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment

Change in cough was calculated based upon the number of coughs per hour in 24 hours at Week 4 and baseline. Results are presented as percent change from baseline. Reported percent change is based on a mixed model for the log-transformed ratio of the number of coughs per hour while asleep at each visit with treatment, week, and treatment-by-week as fixed effect, participants as random effect, and region and the log-transformed coughs per hour while asleep at baseline as covariates. The number of coughs per hour while awake was measured using a cough monitor.

Time frame:
Baseline to Week 4
Reported as:
Geometric mean · percentage change
Percent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment
percentage changeS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Percent Change in Number of Coughs Per Hour While Asleep Following 4 Weeks of Study Treatment-54.43 (-66.61 to -37.80)-53.17 (-65.89 to -35.73)-65.48 (-74.96 to -52.41)-52.73 (-65.30 to -35.61)
SecondaryChange From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment

Cough severity was assessed by the participant by a visual analog scale with numbers from 0 to 100. Results are presented as change from baseline. Reported change is based on a mixed model for the change in weekly cough severity score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the severity score at baseline as covariates. Higher scores indicated higher cough severity.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment
score on a scaleS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Change From Baseline in Weekly Cough Severity Following 4 Weeks of Study Treatment-19.99 (-24.47 to -15.51)-22.95 (-27.42 to -18.47)-28.29 (-32.86 to -23.72)-21.74 (-26.20 to -17.27)
SecondaryChange From Baseline in Leicester Cough Questionnaire (LCQ) Total Score

The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 21. Higher score indicates a better quality of life. Results are presented as change from baseline. Reported change is based on a mixed model for the change in LCQ Total Score after 4 weeks of treatment with treatment, week, and treatment-by-week as fixed effect, participant as random effect, and region (Japan, Europe, or the United States) and the LCQ Score of corresponding domain at baseline as covariates.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · score on a scale
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score
score on a scaleS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score2.80 (2.17 to 3.43)3.10 (2.46 to 3.75)3.86 (3.19 to 4.53)3.17 (2.52 to 3.82)
SecondaryNumber of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points

The LCQ is a patient-reported quality of life (QOL) measure of chronic cough. The questionnaire consists of 19 items to which the participant responds on a 7-point Likert response scale (from 1 to 7). Each item assesses symptoms during cough and the effect of cough on 3 main domains: physical, psychological and social. Domain scores range from 1-7, and the total score ranges from 3 - 2. A higher score indicates a better quality of life.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points
ParticipantsS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Number of Responders Defined as Participants With an Increase in LCQ of ≥ 1.3 Points53566048
SecondaryChange From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)

The ICIQ-SF is a questionnaire used to evaluate the frequency, severity, and impact of urinary incontinence on the quality of life. The questionnaire includes 3 items with responses measured on Likert scales, and 1 item that is measured via a qualitative response. The 3 nominal responses are summed to give the ICIQ score (this total ICIQ-SF score can range from 0 to 21), where a higher score indicates more severe symptoms. The 1 item remaining that is measured via qualitative response is not given a score; rather, the participant selects 1 description out of 8 possible descriptions of this item.

Time frame:
Baseline to Week 4
Reported as:
Mean · score on a scale
Change From Baseline in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)
score on a scaleS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Baseline, Female With Symptoms9.9 ± 5.08.8 ± 5.29.2 ± 4.68.6 ± 4.2
Change at Week 4 - Female With Symptoms-2.2 ± 3.9-1.2 ± 3.4-1.6 ± 3.8-1.2 ± 3.3
Baseline, Female Without Symptoms0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Change at Week 4 - Female Without Symptoms0.9 ± 2.20.1 ± 0.40.5 ± 1.30.3 ± 1.1
Baseline, Male With Symptoms9.5 ± 5.35.0 ± 2.36.7 ± 4.05.0 ± 2.2
Change at Week 4 - Male With Symptoms-2.0 ± 8.3-0.7 ± 2.7-1.0 ± 2.3-0.9 ± 2.2
Baseline, Male Without Symptoms0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Change at Week 4 - Male Without Symptoms0.8 ± 2.41.3 ± 3.20.5 ± 1.40.0 ± 0.0
SecondaryChange From Baseline in Short Form (36) Health Survey (SF-36)

The SF-36 is a 36-item questionnaire to assesses a participant's health status using 8 health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. The mental component reports the average of all the emotionally relevant items and the physical component reports the average of all the physically relevant items. Each component is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. A score of 0 is equal to maximum disability, and a score of 100 indicates no disability. Median change can range from -100 to 100. A positive median change indicates an improved outcome.

Time frame:
Baseline to Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Short Form (36) Health Survey (SF-36)
score on a scaleS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Baseline - Physical Component Score38.4 ± 6.338.6 ± 5.738.1 ± 5.637.8 ± 5.5
Change at Week 4 - Physical Component Score-0.3 ± 5.0-0.9 ± 4.5-0.9 ± 4.6-1.3 ± 5.0
Baseline - Mental Component Score46.1 ± 10.347.1 ± 9.047.5 ± 8.747.2 ± 9.2
Change at Week 4 - Mental Component Score2.2 ± 5.91.9 ± 6.02.6 ± 6.03.3 ± 6.0
SecondaryNumber of Responders as Assessed by Patient Global Impression of Change (PGIC)

The PGIC is a patient-reported measure of overall health status and consists of 1 item adapted from the Clinical Global Impressions scale. The participant selects 1 description out of 7 possible descriptions of this item. The descriptions are numbered from 1 through 7, where lower numbers indicate better quality of life. Participants were considered responders if they reported "Very much improved", "Much improved", or "Minimally improved" from baseline on the PGIC assessment.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Responders as Assessed by Patient Global Impression of Change (PGIC)
ParticipantsS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
Number of Responders as Assessed by Patient Global Impression of Change (PGIC)57727965

Adverse events

Collected over Up to 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-600918 50 mg0/101 (0%)0/101 (0%)5/101 (5%)
S-600918 150 mg0/103 (0%)0/103 (0%)15/103 (14.6%)
S-600918 300 mg0/100 (0%)0/100 (0%)34/100 (34%)
Placebo0/102 (0%)0/102 (0%)10/102 (9.8%)
Most frequent other events
Most frequent other events
EventS-600918 50 mgS-600918 150 mgS-600918 300 mgPlacebo
DysgeusiaNervous system disorders2/10112/10327/1003/102
HeadacheNervous system disorders3/1012/1031/1007/102
HypogeusiaNervous system disorders0/1011/1036/1000/102

Baseline characteristics

Full Analysis Set included all randomized participants who received at least 1 dose of study drug and who had cough monitor assessment at both baseline and at least 1 visit after initiation of study drug administration.

Age, Continuous
Age, Continuous(years)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
Mean58.7 ± 11.257.2 ± 12.556.1 ± 12.456.1 ± 11.557.0 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
Female78756577295
Male22273125105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
Hispanic or Latino534214
Not Hispanic or Latino959892100385
Unknown or Not Reported01001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
American Indian or Alaska Native00022
Asian2525252297
Native Hawaiian or Other Pacific Islander00000
Black or African American31149
White71766972288
More than one race10124
Unknown or Not Reported00000
Average Coughs per Hour in 24 Hours
Average Coughs per Hour in 24 Hours(number of coughs)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
Mean30.40 ± 22.9240.95 ± 64.6836.21 ± 37.9133.85 ± 34.6035.36 ± 43.00
Weekly Severity of Cough
Weekly Severity of Cough(score on a scale)S-600918 50 mgS-600918 150 mgS-600918 300 mgPlaceboTotal
Mean74.8 ± 14.073.6 ± 13.872.6 ± 15.371.6 ± 14.573.1 ± 14.4
08

Study locations

136 sites
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Pulmonary Associates, PA
    Phoenix, Arizona 85032, United States
  • Alliance for Multispecialty Research
    Tempe, Arizona 85283, United States
  • Southern California Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Allergy & Asthma Associates of Southern California dba Southern California Research
    Mission Viejo, California 92691, United States
  • California Medical Research Associates, Inc.
    Northridge, California 91324, United States
  • Center for Clinical Trials, LLC
    Paramount, California 90723, United States
  • Institute of HealthCare Assessment, Inc.
    San Diego, California 92120, United States
  • Sher Allergy Specialist/Center for Cough
    Largo, Florida 33778, United States
  • Medical Research Of Central Florida, LLC
    Leesburg, Florida 34748, United States
  • Lenus Research & Medical Group, LLC
    Sweetwater, Florida 33172, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Sneeze, Wheeze, & Itch Associates, LLC
    Normal, Illinois 61761, United States
  • University of Kansas Medical Center-Hospital
    Kansas City, Kansas 66160, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Abraham Research PLLC
    Fort Mitchell, Kentucky 41017, United States
  • Shionogi Research Site
    Bangor, Maine 04401, United States
  • St. Joseph's Hospital
    Bangor, Maine 04401, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Mayo Clinic Pulmonary Clinical Research Unit
    Rochester, Minnesota 55905, United States
  • Mayo Clinic, Division of Pulmonary and Critical Care Medicine
    Rochester, Minnesota 55905, United States
  • Minnesota Lung Center
    Woodbury, Minnesota 55125, United States
  • University of Missouri Hospital and Clinics, ENT & Allergy Center of Missouri
    Columbia, Missouri 65201, United States
  • University of Missouri Hospital and Clinics, Hearing and Balance Center
    Columbia, Missouri 65201, United States
  • University of Missouri Hospital - Clinical Research Center
    Columbia, Missouri 65212, United States
  • Clayton Sleep Institute, LLC
    Saint Louis, Missouri 63123, United States
  • Associated Specialists in Medicine, PC
    Saint Louis, Missouri 63141, United States
  • The Clinical Research Center, LLC
    Saint Louis, Missouri 63141, United States
  • Montana Medical Research, Inc.
    Missoula, Montana 59808, United States
  • Creighton University Clinical Research Office
    Omaha, Nebraska 68124, United States
  • Atlantic Research Center, LLC
    Ocean City, New Jersey 07712, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • American Health Research Inc
    Charlotte, North Carolina 28207, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28504, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • New Horizons Clinical Research
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Northwest Research Center
    Portland, Oregon 97202, United States
  • Clinical Research Associates of Central PA, LLC
    DuBois, Pennsylvania 15801, United States
  • AAPRI Clinical Research Institute
    Warwick, Rhode Island 02886, United States
  • ADAC Research, PA
    Greenville, South Carolina 29607, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Pharmaceutical Research & Consulting, Inc
    Dallas, Texas 75231, United States
  • MCA Research
    Houston, Texas 77084, United States
  • Metroplex Pulmonary and Sleep Center
    McKinney, Texas 75069, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Allergy and Asthma Care of Waco
    Waco, Texas 76712, United States
  • Allergy Asthma Research Institute
    Waco, Texas 76712, United States
  • Intermountain Clinical Research
    Draper, Utah 84020, United States
  • Tidewater Physicians Multispecialty Group Clinical Research
    Williamsburg, Virginia 23188, United States
  • Allergy, Asthma & Sinus Center, S.C.
    Greenfield, Wisconsin 53228, United States
  • Fakultní Nemocnice Olomouc
    Olomouc, Czech Republic 779 00, Czechia
  • MUDr. I. Čierná-Peterová s.r.o.
    Brandýs nad Labem-Stará Boleslav, 250 01, Czechia
  • Plicní Ambulance Rokycany s.r.o.
    Rokycany, 337 22, Czechia
  • MUDr. Jaroslav Mareš -
    Strakonice, 386 01, Czechia
  • Plicní středisko Teplice s.r.o.
    Teplice, 415 01, Czechia
  • Pneumologie Varnsdorf s.r.o.
    Varnsdorf, 407 47, Czechia
  • Nagoya City University Hospital
    Nagoya, Aichi 467-8602, Japan
  • Fukui Prefectural Hospital
    Fukui-shi, Fukui 910-8526, Japan
  • Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers
    Fukuoka City, Fukuoka 815-8588, Japan
  • Nishi Fukuoka Hospital
    Fukuoka-shi, Fukuoka 819-8555, Japan
  • Iizuka Hospital
    Iizuka, Fukuoka 820-8505, Japan
  • Fukushima Medical University Hospital
    Fukushima-shi, Fukushima 960-1295, Japan
  • Tohno Chuo Clinic
    Mizunami-shi, Gifu 509-6134, Japan
  • Mazda Hospital of Mazda Motor Corporation
    Aki-gun, Hiroshima 735-8585, Japan
  • Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital
    Fukuyama, Hiroshima 7200001, Japan
  • Makita Hospital
    Sapporo-city, Hokkaido 001-0901, Japan
  • Idaimae Minamiyojo Int Clinic
    Sapporo, Hokkaido 064-0804, Japan
  • Nakatani Hospital
    Himeji, Hyogo 672-8064, Japan
  • Kobe University Hospital
    Kobe City, Hyogo 650-0017, Japan
  • Hitachi, Ltd. Hitachinaka General Hospital
    Hitachinaka-shi, Ibaraki 312-0057, Japan
  • National Hospital Organization Ibarakihigashi National Hospital
    Naka-gun, Ibaraki 319-1113, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawa-shi, Ishikawa 9208530, Japan
  • Sakaide City Hospital
    Sakaide-shi, Kagawa 762-8550, Japan
  • Kamei Internal Medicine and Respiratory Clinic
    Takamatsu, Kagawa 761-8073, Japan
  • Fujisawa City Hospital
    Fujisawa, Kanagawa 251-8550, Japan
  • National Hospital Organization Sagamihara National Hospital
    Sagamihara-shi, Kanagawa 252-0392, Japan
  • Kaiseikai Kita Shin Yokohama Internal Medicine Clinic
    Yokohama-shi, Kanagawa 223-0059, Japan
  • Yokohama City Minato Red Cross Hospital
    Yokohama-shi, Kanagawa 231-8682, Japan
  • Kyoto University Hospital
    Kyoto-shi, Kyoto 606-8507, Japan
  • Tohoku Rosai Hospital
    Sendai-City, Miyagi 981-8563, Japan
  • Lee's Clinic
    Osaka-shi, Osaka 531-0073, Japan
  • National Hospital Organization Kinki-Chuo Chest Medical Center
    Sakai-shi, Osaka 591-8555, Japan
  • Japan Organization of Occupational Health and Safety Hamamatsu Rosai Hospital
    Hamamatsu-shi, Shizuoka 430-8525, Japan
  • Shizuoka General Hospital
    Shizuoka-shi, Shizuoka 420-8527, Japan
  • Nihonbashi Medical & Allergy Clinic
    Chuo-ku, Tokyo 103-0022, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Takahashi Medical Clinic
    Kokubunji-shi, Tokyo 185-0014, Japan
  • Senzoku Kokyuuki Allergy Clinic
    Ota-ku, Tokyo 145-0063, Japan
  • KONO Medical Clinic
    Setagaya-ku, Tokyo 157-0072, Japan
  • Yoga Allergy Clinic
    Setagaya, Tokyo 158-0097, Japan
  • Koukokukai Ebisu Clinic
    Shibuya-shi, Tokyo 150-0013, Japan
  • Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai
    Shinagawa-ku, Tokyo 140-8522, Japan
  • Kouwakai Kouwa Clinic
    Toshima-ku, Tokyo 170-0003, Japan
  • Shimonoseki City Hospital
    Shimonoseki-shi, Yamaguchi 750-8520, Japan
  • Prywatny Gabinet lnternistyczno-Alergologiczny
    Bialystok, 15-010, Poland
  • Centrum Medycyny Oddechowej Mroz sp. j.
    Bialystok, 15-044, Poland
  • Centrum Medyczne Pratia Bydgoszcz
    Bydgoszcz, 85-796, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, 81-338, Poland
  • Centrum Medyczne Silmedic Sp. z o. o.
    Katowice, 40-282, Poland

Showing the first 100 of 136 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Dec 2020, 9 months.

Results were first posted in Mar 2024, 3 years 3 months after primary completion. A results delay was requested in Dec 2021.

Of 25 phase 2 interventional studies under Chronic Cough, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Oct 1, 2019
StartActual
Feb 13, 2020
Primary completionActual
Dec 8, 2020
CompletionActual
Dec 28, 2020
Results delay requested
Dec 7, 2021
Results first posted
Mar 27, 2024
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04110054
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Feb 13, 2020
Primary completion
Dec 8, 2020
Completion
Dec 28, 2020
Results posted
Mar 27, 2024
Last update
Mar 27, 2024

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion